Twenty Years of Experience; Hemophilic Arthropathy Rates and Correlation with Treatment Modalities: Ege Hemophilia Council Data. A Single-Center Experience Among 583 Turkish Patients: A Cohort Study
Makaleler > Tam Makale · 2023
Yazarlar: Süleyman Emre KARAÜZÜM, Ramazan Kaan KAVAKLI
Turkiye Klinikleri Journal of Medical Sciences, Uluslararası, Scopus, 2023, cilt 43, ss 350-359
DOI: 10.5336/medsci.2023-99918
Özet
Objective: This study aims to investigate the evolving landscape of hemophilia care over two decades, focusing on patients with hemophilic arthropathy. We analyze demographic shifts, treatment patterns, and their impact on patient outcomes, providing insights into the challenges and progress in managing this rare but debilitating disorder. Material and Methods: Data from the Ege Hemophilia Joint Council spanning 20 years, covering 583 patients, were examined. Patient demographics, treatment patterns, and outcomes were comprehensively evaluated. The analysis involved descriptive statistics, comparative analyses, regression models, subgroup assessments, and temporal trend visualizations. Results: Demographically, the study revealed an increasing average age of patients, with a predominant male population. Hemophilia A and B patients, primarily those with severe cases, were the focus of the study, with 10% of patients having inhibitors. The Ege Hemophilia Joint Council's reach extended to patients from across Türkiye. Prophylactic treatment witnessed a rising trend, particularly in the last decade. Joint complications, especially knee issues, remained a primary concern, with emerging trends in ankle involvement and decreasing elbow complications. Use of orthopedic aids declined, indicating improved care. Conclusion: This research highlights the importance of tailored care, prophylaxis, and timely orthopedic interventions in managing hemophilic arthropathy. The Ege Hemophilia Joint Council serves as a national center for comprehensive care. While progress is evident, the study emphasizes the ongoing commitment needed to ensure accessible and effective treatment, reducing the impact of hemophilic arthropathy on patients' lives.